Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population

DNA and Cell Biology

Volumn 32, Issue 7, 2013, Pages 414-419

  Chen, Jialu ^a   Zhu, Bo ^b   Chen, Jingwei ^a   Li, Yongjian ^a  

^a Suzhou Hospital of Traditional Chinese Medicine   (China)

^b Jiangsu Hospital of Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; MESSENGER RNA; PROLINE; PROTEIN MDM2; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT DISEASE; AGED; ALLELE; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84879935263     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2012.1900     Document Type: Article

References (38)

1. Ara S, Lee PS, Hansen MF, Saya H. (1990). Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 18, 4961. (Pubitemid 20280142)
2. Bittenbring J, Parisot F, Wabo A, et al. (2008). MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer 8, 116.
3. Bond GL, Hu W, Bond EE, et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602. (Pubitemid 39535748)
4. Brennan P. (2002). Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 23, 381-387. (Pubitemid 34257617)
5. Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. (2008). Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis 29, 2120-2125.
6. Coutts AS, Adams CJ, La Thangue NB. (2009). p53 ubiquitination by Mdm2: a never ending tail? DNA Repair (Amst) 8, 483-490.
7. Döhner H, Fischer K, Bentz M, et al
8. Donehower LA, Harvey M, Slagle BL, et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221.
9. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33, 357-365. (Pubitemid 36278852)
10. Eischen CM, Lozano G. (2009). p53 and MDM2: antagonists or partners in crime? Cancer Cell 15, 161-162.
11. Fenaux P, Jonveaux P, Quiquandon I, et al. (1992). Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia 6, 42-46.
12. Freedman DA, Levine AJ. (1999). Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth GH.A. Clowes Memorial Award Lecture. Cancer Res 59, 1-7. (Pubitemid 29062945)
13. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, et al. (2009). FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer 125, 1735-1738.
14. Greaves MF, Wiemels J. (2003). Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 3, 639-649. (Pubitemid 37328819)
15. Gryshchenko I, Hofbauer S, Stoecher M, et al. (2008). MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 26, 2252-2257.
16. Gustafsson B, Christenson B, Hjalmar V, Winiarski J. (2000). Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol 34, 117-124. (Pubitemid 30090477)
17. Hoelzer D. (1992). Prognostic factors in acute lymphoblastic leukemia. Leukemia 6 Suppl 4, 49-51.
18. Hong Y, Miao X, Zhang X, et al. (2005). The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65, 9582-9587. (Pubitemid 41508029)
19. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. (2007). MDM2 promoter polymorphism SNP309 contributes to tumor sus-ceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16, 2717-2723. (Pubitemid 351196328)
20. Kruse JP, Gu W. (2009). Modes of p53 regulation Cell 137, 609-622.
21. Lehmann U, Kreipe H. (2001). Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 25, 409-418. (Pubitemid 34164013)
22. Malkin D. (1993). p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 66, 83-92. (Pubitemid 23155343)
23. Malkin D, Li FP, Strong LC, et al. (1990). Germ line p53 muta-tions in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238. (Pubitemid 120031831)
24. Matakidou A, Eisen T, Houlston RS. (2003). TP53 polymor-phisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18, 377-385. (Pubitemid 36850206)
25. Momand J, Jung D, Wilczynski S, Niland J. (1998). The MDM2 gene amplification database. Nucleic Acids Res 26, 3453-3459. (Pubitemid 28347214)
26. Nayak MS, Yang JM, Hait WN. (2007). Effect of a single nucle-otide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 67, 5831-5839. (Pubitemid 46985017)
27. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. (2002). The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19, 607-614. (Pubitemid 34556481)
28. Palmero EI, Schüler-Faccini L, Caleffi M, et al. (2008). Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 261, 21-25.
29. Phang BH, Linn YC, Li H, Sabapathy K. (2008). MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 44, 760-766.
30. Rayburn E, Zhang R, He J, Wang H. (2005). MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5, 27-41. (Pubitemid 40321798)
31. Runnebaum IB, Tong XW, Moebus V, Heilmann V, Kieback DG, Kreienberg R (1994). Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum Genet 93, 620-624. (Pubitemid 24166485)
32. Sugimoto K, Toyoshima H, Sakai R, et al. (1991). Mutations of the p53 gene in lymphoid leukemia. Blood 77, 1153-1156.
33. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matla-shewski G. (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19, 1092-1100. (Pubitemid 29046852)
34. Vousden KH, Lu X. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604. (Pubitemid 37328926)
35. Xiong X, Wang M, Wang L, et al. (2009). Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 33, 1454-1458.
36. Yang M, Guo Y, Zhang X, et al. (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their asso-ciations with risk of gastric cardia cancer. Carcinogenesis 28, 1996-2001. (Pubitemid 47500614)
37. Ye S, Dhillon S, Ke X, Collins AR, Day IN. (2001). An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29, E88.
38. Zhang X, Miao X, Guo Y, et al. (2006). Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27, 110-117. (Pubitemid 43042973)